The effects of pituitary adenylate cyclase activating polypeptide in renal ischemia/reperfusion

László, Eszter; Kiss, P.; Horváth, Gabriella; Stella, Péter; Tamás, Andrea; Reglődi, Dóra

doi:10.1556/abiol.65.2014.4.1

Cited by 12 publications

(5 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Preservation of morphological structure of small intestine after ligation of mesenteric artery followed by reperfusion was accompanied by decreased oxidative stress and increased anti-oxidant capacity in PACAP-treated animals [ 97 , 98 ]. Similar results have been obtained in the kidney [ 99 ]. Both homo- and heterozygous PACAP knockout mice showed increased injury after renal artery clamping [ 100 , 101 ].…”

Section: Pacap In Cardiac and Other Peripheral Ischemic Conditionssupporting

confidence: 89%

Protective effects of PACAP in ischemia

et al. 2018

View full text Add to dashboard Cite

Pituitary adenylate cyclase activating polypeptide (PACAP) is an ubiquitous peptide involved, among others, in neurodevelopment, neuromodulation, neuroprotection, neurogenic inflammation and nociception. Presence of PACAP and its specific receptor, PAC1, in the trigeminocervical complex, changes of PACAP levels in migraine patients and the migraine-inducing effect of PACAP injection strongly support the involvement of PACAP/PAC1 receptor in migraine pathogenesis. While antagonizing PAC1 receptor is a promising therapeutic target in migraine, the diverse array of PACAP’s functions, including protection in ischemic events, requires that the cost-benefit of such an intervention is well investigated by taking all the beneficial effects of PACAP into account. In the present review we summarize the protective effects of PACAP in ischemia, especially in neuronal ischemic injuries, and discuss possible points to consider when developing strategies in migraine therapy interfering with the PACAP/PAC1 receptor system.

show abstract

Section: Pacap In Cardiac and Other Peripheral Ischemic Conditionssupporting

confidence: 89%

Protective effects of PACAP in ischemia

et al. 2018

View full text Add to dashboard Cite

show abstract

“…These include their roles in inflammatory disorders[10-14]; immune/autoimmune diseases[10, 11]; neurodevelopment/behavior[15-17]; neuroprotection/neurodegenerative disorders[18-23]; pulmonary diseases(asthma, etc. )[24]; sepsis[25]; learning/memory disorders[26]; CNS/neurological disorders[14, 21, 27-29]; diabetes[30, 31]; migraine[32, 33]; stress-responses/disorders[34, 35]; renal injuries[20] and general reviews of their signaling/ pharmacology as well their roles in physiology/pathophysiology[3••, 5, 6, 36, 37]. In this review the roles of VIP/PACAP in neoplastic processes, which has generally not been dealt with recently[38, 39], will be concentrated on.…”

Section: Introductionmentioning

confidence: 99%

Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer

Moody¹,

Nuche-Berenguer

Jensen

2016

Current Opinion in Endocrinology, Diabetes &Amp; Obesity

View full text Add to dashboard Cite

Purpose of review To summarize the roles of VIP/PACAP and their receptors(VPAC1, VPAC2/PAC1) in human tumors as well as their role in potential novel treatments. Recent findings Considerable progress has been made in understanding of the effects of VIP/PACAP on growth of various tumors as well as in the signaling cascades involved, especially of the role of transactivation of the Epidermal growth factor(EGF) family. The overexpression of VPAC1/2, PAC1 on a number of common neoplasms (breast, lung, prostate, CNS, neuroblastoma) is receiving increased attention both as a means of tumor imaging the location and extent of these tumors, as well as for targeted directed treatment, by coupling cytotoxic agents to VIP/PACAP analogues. Summary VIP/PACAP has prominent growth effects on a number of common neoplasms, which frequently overexpressed the three subtypes of their receptors. The increased understanding of their signaling cascades, effect on tumor growth/differentiation, and the use of the overexpression of these receptors for localization/targeted cytotoxic delivery, are all suggesting possible novel tumor treatments.

show abstract

“…Ischemic injury often occurs in patients with diabetes during the peri-operative period. Diabetic nephropathy with ischemia/reperfusion (I/R) injury is also closely related to oxidative stress ( 4 , 5 ). However, the underlying mechanisms responsible for the adverse effects caused by oxidative stress on renal injury induced by hyperglycemia with I/R insults have not yet been completely elucidated.…”

Section: Introductionmentioning

confidence: 99%

Overexpression of DJ-1 reduces oxidative stress and attenuates hypoxia/reoxygenation injury in NRK-52E cells exposed to high glucose

Shen

Sun

Xia

et al. 2016

International Journal of Molecular Medicine

View full text Add to dashboard Cite

Patients with diabetes are more vulnerable to renal ischemia/reperfusion (I/R) injury, which is implicated in hyperglycemia-induced oxidative stress. We previously reported that the hyperglycemia-induced inhibition of DJ-1, a novel oncogene that exhibits potent antioxidant activity, is implicated in the severity of myocardial I/R injury. In the present study, we aimed to explore the role of DJ-1 in hypoxia/reoxygenation (H/R) injury in renal cells exposed to high glucose (HG). For this purpose, NRK-52E cells were exposed to HG (30 mM) for 48 h and then exposed to hypoxia for 4 h and reoxygenation for 2 h, which significantly decreased cell viability and superoxide dismutase (SOD) activity, and increased the malondialdehyde (MDA) content, accompanied by a decrease in DJ-1 protein expression. The overexpression of DJ-1 by transfection with a DJ-1 overexpression plasmid exerted protective effects against HG-induced H/R injury, as evidenced by increased CCK-8 levels and SOD activity, the decreased release of lactate dehydrogenase (LDH) and the decreased MDA content, and increased nuclear factor (erythroid-derived 2)-like 2 (Nrf2) and heme oxygenase-1 (HO-1) expression. Similar effects were observed following treatment with the antioxidant, N-acetylcysteine. These results suggest that the overexpression of DJ-1 reduces oxidative stress and attenuates H/R injury in NRK-52E cells exposed to HG.

show abstract

The effects of pituitary adenylate cyclase activating polypeptide in renal ischemia/reperfusion

Cited by 12 publications

References 52 publications

Protective effects of PACAP in ischemia

Protective effects of PACAP in ischemia

Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer

Overexpression of DJ-1 reduces oxidative stress and attenuates hypoxia/reoxygenation injury in NRK-52E cells exposed to high glucose

Contact Info

Product

Resources

About